Enterprise value to EBITDA forward of Codexis, Inc. – NASDAQ:CDXS
This article displays the "Enterprise value to EBITDA forward" for Codexis, Inc. (NASDAQ:CDXS) on the TradingView platform. It shows that the market is currently closed with no trades, and provides standard stock market information along with various TradingView features and legal disclaimers.
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results
This article analyzes Codexis, Inc.'s recent earnings report and its impact on analyst price targets. Following the results, analysts have provided updated valuations, with the average price target now standing at US$6.58, suggesting a potential upside from the current share price. The article likely details the reasoning behind these revised targets and key factors influencing investor sentiment.
Price to sales forward of Codexis, Inc. – NASDAQ:CDXS
This page displays the forward Price to Sales ratio for Codexis, Inc. (NASDAQ: CDXS). It provides financial data for the company within the Process Industries / Chemicals: Specialty sector, indicating that the market was closed at the time of access with no trades recorded.
Codexis, Inc. Actuals & Estimates (NASDAQ:CDXS)
This article provides a detailed overview of Codexis, Inc. (NASDAQ:CDXS) stock performance, financial actuals, and analyst estimates. It highlights key financial metrics, stock price dynamics, future forecasts, and answers frequently asked questions regarding the company's market cap, earnings dates, revenue, and employee count.
CDXS Forecast — Price Target — Prediction for 2027
This article provides an overview of Codexis, Inc. (CDXS) stock, including its current price, analyst forecasts, and key financial metrics. It highlights recent stock performance, revenue, earnings, and market capitalization, along with upcoming earnings dates. The article concludes with information on how to buy CDXS stocks and general investment advice.
Codexis Inc (CDXS) Financial Health: Profitability & Balance Sheet Analysis
Codexis Inc (CDXS) has a financial score of 8.64, ranking 37th in the Biotechnology & Medical Research industry, indicating stable financial status and high operating efficiency. The company reported a significant year-over-year revenue increase of 102.15% to $15.25M, with net profit rising by 57.93%. Despite these positive indicators, several relevant financial data points including cash and cash equivalents, total assets, total liabilities, free cash flow, operating profit, and income after tax have not yet been disclosed by the company.
Codexis shareholders elect directors and approve proposals at annual meeting
Codexis, Inc. (NASDAQ:CDXS) held its 2026 Annual Meeting of Stockholders where shareholders elected Stephen G. Dilly, Raymond De Vrè, and Rahul Singhvi to the board of directors for three-year terms. The meeting also saw the ratification of KPMG LLP as the company's independent registered public accounting firm and a non-binding advisory approval of executive officer compensation. These events follow a 58% year-to-date surge in Codexis shares and positive Q1 2026 financial results.
Form 8K Codexis Inc For: 22 June By Investing.com
This article from Investing.com announces the filing of a Form 8K by Codexis Inc. on June 22. It lists various stock market indices, commodities, and individual stocks with their current prices and daily changes. The article also highlights popular news related to tech companies and investment trends.
Codexis (CDXS) shareholders back board nominees, KPMG and pay plan
Codexis, Inc. shareholders voted at the 2026 Annual Meeting to re-elect Stephen G. Dilly, Raymond De Vré, and Rahul Singhvi to the board for three-year terms. They also ratified KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the compensation of the named executive officers on a non-binding advisory basis. The results indicate strong shareholder support for the company's current governance and compensation practices.
Codexis (CDXS) director receives option grant for 66,350 shares
Codexis (CDXS) director Esther Martinborough received a stock option grant for 66,350 shares at an exercise price of $2.48 per share. These options vest upon the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on her continued board service, and expire on June 17, 2036. This transaction is detailed in a Form 4 SEC filing, and after this grant, Martinborough directly holds options for 66,350 shares.
Codexis (NASDAQ: CDXS) director receives 66,350 options vesting in one year
Codexis (NASDAQ: CDXS) director Rahul Singhvi was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options vest fully on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, conditional on his continued service as a director. This grant increased his option holdings from this award to 66,350 shares, and it is considered a compensation-related award rather than an open-market transaction.
Codexis (CDXS) director David V. Smith granted 66,350 stock options at $2.48
Codexis (CDXS) director David V. Smith was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. This grant serves as equity compensation and is not an open-market trade. The options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on Smith's continued service as a director.
Director at Codexis (CDXS) receives 66,350 stock options grant
Codexis (CDXS) director Cynthia Collins was granted 66,350 stock options with an exercise price of $2.48 per share. These options vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting and expire in 2036. This transaction is a form of equity compensation, not an open market purchase or sale of shares.
CODEXIS (CDXS) director receives 66,350 stock options at $2.48 strike price
CODEXIS director Christos Richards was granted 66,350 stock options with an exercise price of $2.48 per share. These options, awarded at no cost, will vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided Richards continues his board service. The options are set to expire on June 17, 2036, and represent a direct acquisition by the director.
Codexis (CDXS) director Parker H. Stewart receives 66,350 stock options
Codexis (CDXS) director Parker H. Stewart has been granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on his continued service as a director. This transaction is classified as an acquisition, not a market purchase or sale.
Codexis (CDXS) director Raymond De Vre awarded 66,350 stock options at $2.48
Codexis (CDXS) director Raymond De Vre was granted 66,350 stock options with an exercise price of $2.48 per share, expiring on June 17, 2036. The options will vest in full on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, contingent on his continued service. This award is compensation-related and not an open-market transaction.
Codexis (CDXS) grants director 66,350 stock options at $2.48
Codexis (CDXS) director Stephen George Dilly was granted 66,350 stock options at an exercise price of $2.48 per share, as part of his compensation package. These options will vest on the earlier of the first anniversary of the grant date or the next annual stockholder meeting, provided he continues his service to the company. The options have an expiration date of June 17, 2036, and are not a market purchase, but rather a compensation award.
Codexis Inc (CDXS) Shareholder Structure: Major Shareholders & Institutional Holdings
The article details the shareholder structure of Codexis Inc (CDXS), listing its major shareholders and their proportions, including abrdn Inc., Opaleye Management Inc., and BlackRock Institutional Trust Company, N.A. It also categorize shareholders by type, such as investment advisors and hedge funds. Furthermore, the report provides institutional shareholding trends over several quarters and recent shareholder activity with changes in holdings for key investors.
Codexis Inc (CDXS) Institutional Confidence
Codexis Inc (CDXS) has an institutional shareholding score of 7.00, placing it 81st out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion is 73.00%, a 13.55% decrease quarter-over-quarter. Bill Nygren, holding 332.07K shares, is the largest institutional shareholder despite an 88.59% decrease in holdings.
Codexis Inc (CDXS) Earnings Forecast: Future EPS & Revenue Growth Estimates
Codexis Inc (CDXS) has an earnings forecast score of 8.00, ranking 163 out of 388 in its industry. Analysts have set an average price target of $7.00, with a consensus "Buy" rating based on 7 analysts. The company's expected revenue for the next quarter is $14.35 million, and its EPS for the previous quarter was $0.11, with the next expected at -$0.14.
Codexis Inc (CDXS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a revenue breakdown for Codexis Inc (CDXS), detailing its financial performance by region. As of April 6, the company's total revenue was $70.49 million, with America contributing the largest share at 61.85%. Data for business segments and profit contribution were not yet disclosed.
CDXS: All proposals, including director elections and auditor ratification, were approved without contest
During the Codexis, Inc. (CDXS) 2026 AGM, all proposals, including director elections and auditor ratification, were approved without contest. A quorum was confirmed, and no stockholder questions were raised. The voting results for these approved proposals will be officially reported on Form 8-K within four business days.
Cantor Fitzgerald reiterates Codexis stock rating on oligo platform
Cantor Fitzgerald reaffirmed an Overweight rating and an $11.00 price target for Codexis, Inc., citing the significant potential of oligonucleotide therapeutics and Codexis' enzymatic ECO Synthesis Manufacturing Platform. The firm highlighted that the platform is well-positioned to address the manufacturing limitations currently constraining the rapidly expanding drug class. This reiteration follows Codexis' Q1 2026 financial results, which exceeded analyst expectations for both EPS and revenue.
Cantor Fitzgerald reiterates Codexis stock rating on oligo platform
Cantor Fitzgerald has reiterated an Overweight rating and an $11.00 price target for Codexis, Inc. (NASDAQ:CDXS), highlighting the significant opportunity for its enzymatic ECO Synthesis Manufacturing Platform in the rapidly expanding oligonucleotide therapeutics market. This reaffirmation follows a fireside chat with Dr. Art Levin, an expert in oligonucleotides, who believes the field is poised for growth despite current manufacturing limitations. Additionally, Codexis recently surpassed first-quarter 2026 financial expectations with better-than-forecasted EPS and revenues.
Codexis director Raymond de Vre sells $6,173 in shares
Codexis director Raymond De Vre sold 2,605 shares of the company's common stock for $6,173 to cover tax liabilities from Restricted Stock Units. Following the sale, Mr. De Vre directly holds 84,811 shares. This transaction occurs after Codexis shares surged 44% in six months and the company reported better-than-expected Q1 2026 financial results, with EPS of -0.1 and revenues of $15.2 million.
Codexis director Raymond de Vre sells $6,173 in shares
Codexis director Raymond de Vre sold 2,605 shares of the company's common stock for $6,173 to cover tax liabilities from vested Restricted Stock Units. Post-transaction, he directly holds 84,811 shares. This sale follows a significant 44% surge in Codexis shares over the past six months, with the stock still considered undervalued according to InvestingPro analysis, despite its high volatility.
Codexis (CDXS) director De Vre sells 2,605 shares to cover RSU tax liability
Codexis director Raymond De Vre sold 2,605 shares of common stock for $2.37 per share on June 11, 2026. This sale was primarily to cover tax liabilities associated with vested Restricted Stock Units (RSUs) and is considered a mechanical transaction rather than a discretionary investment decision. Following the sale, De Vre still holds 84,811 shares, including 31,897 RSUs, maintaining a significant stake in the company.
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
Codexis highlighted new advancements in RNA therapeutic manufacturing at TIDES USA 2026, focusing on its ECO Synthesis Manufacturing Platform. The company demonstrated full-length siRNA synthesis with precise stereochemical control and introduced the ability to initiate enzymatic RNA synthesis from a single nucleotide. These innovations aim to improve scalability, sustainability, and potency in RNA therapeutics manufacturing.
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
Codexis announced advancements in RNA therapeutic manufacturing at TIDES USA 2026, showcasing how its ECO Synthesis Manufacturing Platform is improving siRNA production. The company demonstrated precise stereochemical control in full-length siRNA synthesis for the first time and introduced the ability to initiate enzymatic RNA synthesis from a single nucleotide. These innovations aim to enhance efficacy, scalability, and sustainability in the production of next-generation RNA therapeutics.
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
Codexis, a company specializing in enzymatic solutions, showcased its ECO Synthesis® Manufacturing Platform at TIDES USA 2026, demonstrating progress in RNA therapeutic manufacturing. The company highlighted new data on full-length siRNA synthesis with precise stereochemical control and the ability to initiate enzymatic RNA synthesis from a single nucleotide. These advancements aim to improve the scalability, sustainability, and potency of RNA therapeutics, addressing key industry challenges.
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
Codexis, a provider of enzymatic solutions, shared advancements in RNA therapeutic manufacturing at TIDES USA 2026. The company highlighted its ECO Synthesis® Manufacturing Platform, which now enables stereochemical control for siRNA production and eliminates the need for chemically-synthesized starter oligonucleotides. These innovations aim to improve efficacy, scalability, and sustainability in RNA manufacturing.
Codexis highlights stereochemistry advances for scalable RNA manufacturing at TIDES USA
Codexis announced significant advancements in RNA therapeutic manufacturing at TIDES USA 2026, showcasing its ECO Synthesis® Manufacturing Platform. The company demonstrated full-length siRNA synthesis with precise stereochemical control and introduced the ability to initiate enzymatic RNA synthesis from a single nucleotide. These innovations are aimed at improving the scalability, sustainability, and quality of RNA therapeutics.
Q3 2025 Codexis Inc Earnings Call Transcript
Codexis Inc. (CDXS) held its Q3 2025 earnings call, revealing both positive strategic developments and financial challenges. The company secured a supply assurance agreement with Merck and is transitioning to a full-service manufacturing innovator with 11 revenue-generating contracts, while also expanding its oligonucleotide manufacturing capabilities. However, total revenues decreased, R&D expenses increased, and the company reported a net loss for the quarter, leading to a restructuring and headcount reduction to align with its new strategic focus.
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results
Analysts are re-evaluating Codexis, Inc. (NASDAQ:CDXS) after its recent quarterly earnings report, which showed solid revenues and reduced statutory losses. Despite an unchanged revenue forecast for 2026, analysts have become slightly more optimistic about losses per share, though the consensus price target has fallen to US$6.58 due to ongoing profitability concerns. There is a wide range in individual analyst valuations, highlighting diverging views on the company's future performance.
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results
Analysts have re-evaluated Codexis, Inc. (CDXS) after its latest quarterly results, which showed stronger-than-expected revenues of US$15m and lower losses per share at US$0.10. Despite an improved sentiment regarding future losses, the consensus price target has been reduced by 7.1% to US$6.58 due to ongoing profitability concerns and an anticipated revenue decline of 5.0% in 2026, contrasting with industry growth.
Number of shareholders of Codexis, Inc. – NASDAQ:CDXS
This article provides details on the number of shareholders for Codexis, Inc. (NASDAQ: CDXS). It is an excerpt from a financial data platform, likely TradingView, showing the company's stock information and general market data sources. The page highlights basic financial information access for the company.
Codexis Reports First Quarter 2026 Financial Results
Codexis reported first-quarter 2026 revenues of $15.2 million, reaffirming its full-year guidance of $72 million to $76 million, and expects its current cash to fund operations through the end of 2027. The company highlighted advancements in its ECO Synthesis manufacturing platform for RNA therapeutics and plans to present new data at the upcoming TIDES USA annual meeting. Financial results showed a reduced net loss compared to the previous year, driven by increased revenue and decreased operating expenses.
Craig-Hallum Maintains Codexis(CDXS.US) With Buy Rating, Announces Target Price $9
Craig-Hallum has reiterated its Buy rating on Codexis (CDXS.US) and set a target price of $9. This indicates a positive outlook from the firm regarding the company's stock performance.
Codexis reiterates $72M-$76M 2026 revenue outlook while targeting 0.5 kilogram ECO Synthesis scale by year-end
Codexis has reaffirmed its revenue guidance of $72 million to $76 million for 2026, while also announcing plans to scale its ECO Synthesis to 0.5 kilograms by the end of the current year. This target highlights the company's focus on advancing its synthesis technology.
Codexis: Q1 Earnings Snapshot
Codexis Inc. (CDXS) reported a Q1 net loss of $8.7 million, or 10 cents per share. The company's revenue for the quarter was $15.2 million, surpassing analyst expectations of $15 million. Codexis anticipates full-year revenue to be between $72 million and $76 million.
Codexis Reports First Quarter 2026 Financial Results
Codexis (NASDAQ: CDXS) reported first-quarter 2026 revenues of $15.2 million, reaffirming its full-year guidance of $72 million to $76 million. The company announced it has $65.1 million in cash, cash equivalents, and short-term investments, which is expected to fund operations through the end of 2027. Key upcoming milestones include three presentations at the TIDES USA annual meeting and applying for a building permit for its ECO GMP Manufacturing Center.
Earnings call transcript: Codexis beats Q1 2026 EPS forecast, stock rises By Investing.com
Codexis Inc. (CDXS) reported strong Q1 2026 financial results, surpassing analyst expectations with an EPS of -0.1 against a forecasted -0.16 and revenues of $15.2 million, exceeding the $14.79 million anticipation. This performance led to a 1.5% increase in after-hours trading, driven by significant year-over-year revenue growth and improved gross margins, particularly due to the Merck Technology Transfer Agreement. The company is actively advancing its ECO Synthesis manufacturing platform for RNA medicine, aiming to address future production bottlenecks, and expects current cash reserves to fund operations through 2027.
Codexis, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026
Codexis, Inc. announced its earnings results for the first quarter ended March 31, 2026. The company reported a significant increase in revenue, reaching USD 15.25 million compared to USD 7.54 million in the prior year. Additionally, Codexis reduced its net loss to USD 8.7 million from USD 20.69 million year-over-year, with a basic and diluted loss per share of USD 0.1, an improvement from USD 0.25 previously.
Codexis: Q1 Earnings Snapshot
Codexis Inc. (CDXS) reported a first-quarter loss of $8.7 million, or 10 cents per share. Despite the loss, the company's revenue of $15.2 million for the period surpassed Street forecasts of $15 million. Codexis anticipates full-year revenue to be between $72 million and $76 million.
Revenue surges as Codexis (CDXS) narrows quarterly loss and manages debt load
Codexis Inc. (CDXS) reported a significant improvement in its financial performance for the quarter ended March 31, 2026, with total revenue more than doubling to $15.2 million from $7.5 million in the prior year. This growth was driven by increased product sales and substantial research and development revenue, including deferred revenue recognition from a Merck licensing agreement. The company also narrowed its net loss to $8.7 million from $20.7 million, attributing this to revenue growth and reduced operating expenses, while maintaining adequate liquidity of $65.1 million despite $40.5 million in long-term debt.
Codexis says it has cash through 2027 as siRNA plans advance
Codexis (NASDAQ: CDXS) announced Q1 2026 revenue of $15.2 million, a significant increase from Q1 2025, and reaffirmed its full-year guidance of $72–$76 million. The company reported a narrowed net loss of $8.7 million and stated its $65.1 million in cash and short-term investments are sufficient to fund operations through the end of 2027. Codexis highlighted advancements in its ECO Synthesis® platform, including upcoming presentations on siRNA stereochemistry and plans for an ECO GMP Manufacturing Center.
Codexis (NASDAQ: CDXS) Q1 2026 revenue hits $15.2M as net loss shrinks
Codexis (NASDAQ: CDXS) reported strong Q1 2026 financial results, with revenue nearly doubling to $15.2 million from $7.5 million in the prior year, driven by increased product and R&D revenue. The company significantly narrowed its net loss to $8.7 million from $20.7 million, improving loss per share to $0.10. Codexis reiterated its full-year 2026 financial guidance and highlighted advancements in its ECO Synthesis manufacturing platform for RNA therapeutics.
Codexis: Q1 Earnings Snapshot
Codexis Inc. (CDXS) reported a Q1 loss of $8.7 million, or 10 cents per share. The company's revenue reached $15.2 million, surpassing analyst forecasts of $15 million. Codexis anticipates full-year revenue to be between $72 million and $76 million.
Codexis: Q1 Earnings Snapshot
Codexis Inc. reported a first-quarter loss of $8.7 million, or 10 cents per share. The company's revenue of $15.2 million exceeded analyst forecasts of $15 million. Codexis expects its full-year revenue to be between $72 million and $76 million.
Opaleye (NASDAQ: CDXS) holds 7.47% of Codexis, 6.785M shares
Opaleye Management Inc., along with Opaleye, L.P. and James Silverman, has reported beneficial ownership of 6,785,000 shares of Codexis (CDXS) common stock, which represents 7.47% of the company's class. This information was disclosed in an amended SCHEDULE 13G/A filing. The filing indicates that the percentage is calculated based on 90,869,349 common shares outstanding as of March 5, 2026, and includes 120,000 shares held in separate managed accounts.
